Denmark· DK-28106828622
Lercanidipinhydrochlorid "Omniapharm"
A lercanidipine product containing lercanidipinhydrochlorid, registered in Denmark by Orifarm A/S. The same ATC class is registered in 16 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Lercanidipine is registered in 16 of 19 countries.
Countries holding a registration under ATC C08CA13 (lercanidipine), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Lercanidipine · ATC C08CA13
16 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of lercanidipine costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.14 in France to $0.36 in Switzerland — a ×2.6 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lercanidipine · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.36
- ES Spain$0.25
- IT Italy$0.21
- FR France$0.14
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- LERCANIDIPINHYDROCHLORID
- Manufacturer
- Orifarm A/S
- Country
- Denmark (DK)
- ATC code
- C08CA13
- ATC class
- Lercanidipine
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106828622
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for lercanidipine.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lercanidipine · interactions on record
2 records
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under C08CA13
Lercanidipine, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c92cd585-e33b-4e7e-b0de-399c1026666d GET /v1/drugs/c92cd585-e33b-4e7e-b0de-399c1026666d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "20 mg",
"auth_role": "DKMA",
"dk_drugid": "28106828622",
"substance": "LERCANIDIPINHYDROCHLORID",
"auth_procedure": "Par-Imp",
"in_medicinpriser": false,
"registration_date_serial": "44902"
}See everything about lercanidipine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.